outcomes in patients with coronary artery disease (CAD) alone (n = 715, 84.0%) and with both CAD and PVD (n = 136).
Results. -At a median follow-up of 18.6 months, both groups reached recommended secondary prevention goals and showed no significant differences in rates of drug prescription. PVD was not associated with minor cardiovascular events (hazard ratio [HR] 1.32, 95% confidence interval [CI] 0.57-3.02) but remained independently associated with major (HR 2.15, 95% CI 1.12-4.13) and total (HR 1.76, 95% CI 1.05-2.93) cardiovascular events. Compared to patients with CAD alone, this risk was significantly higher in CAD patients with both PVD and diabetes (HR 2.87, 95% CI 1.52-5.43), but not in PVD patients without diabetes (HR 1.35, 95% CI 0.71-2.56) or diabetic patients without PVD (HR 1.11, 95% CI 0.68-1.81).
Conclusion. -Despite optimization of risk-factor control and drug prescription after ACS, patients with both PVD and diabetes carry a 2.9-fold higher risk of cardiovascular events at 18-month follow-up versus patients with CAD alone. This excess risk was not significant in PVD patients without diabetes or in diabetic patients without PVD. © 2010 Elsevier Masson SAS. All rights reserved. 
MOTS CLÉS

Background
Peripheral vascular disease (PVD) is associated with a marked increased risk of cardiovascular events [1] [2] [3] . Patients with known coronary artery disease (CAD) have a poorer prognosis when they have coexisting PVD [4] [5] [6] [7] [8] .
While secondary prevention guidelines for patients with CAD and other atherosclerotic vascular diseases are identical in their recommendations [9] [10] [11] [12] , patients with PVD are less likely than those with CAD to be prescribed the recommended therapies [13] [14] [15] . Even in patients with known CAD, contemporary data show a lower rate of drug prescription after myocardial infarction when PVD is present.
This could in part explain the higher mortality and morbidity observed in the PVD population [16, 17] . The optimal use of evidence-based therapies for secondary prevention is expected to improve modifiable major risk factors, and subsequently reduce cardiovascular morbidity and mortality. However, evidence of their clinical benefit remains poorly defined in PVD subjects.
The aim of this study was to assess whether a global atherosclerosis management programme combined with optimal secondary prevention could benefit high-risk PVD patients after an acute coronary syndrome (ACS). We hypothesized that an aggressive evidence-based drug and lifestyle intervention programme implemented in patients with an ACS would be equally beneficial, firstly in improving risk profile, and secondly in reducing the higher morbidity and mortality rates observed in ACS patients with versus without coexisting PVD.
Patients and methods
Between January 2002 and June 2005, a cohort of consecutive patients hospitalized for an established ACS in Bordeaux Heart Hospital Intensive Care Unit, and in whom a coronary angiogram during the acute phase was performed, was enrolled at the Center of Exploration, Prevention and Treatment of Atherosclerosis (CEPTA) three days after the ACS. The CEPTA programme has been described elsewhere [18] . Briefly, it comprised initiation of secondary prevention measures before hospital discharge, including prescription of optimal treatment, and an extensive evaluation of cardiovascular risk factors, myocardial disease and atherosclerotic burden at three months. Discharge therapy was adapted to cardiac and vascular status and risk factors in accordance with international guidelines [19, 20] . At follow-up, a questionnaire was sent to each patient to determine lifestyle habits, current treatments and cardiovascular or other outcomes.
Acute-phase management
ACS was defined and treated according to the American College of Cardiology guidelines [20] . An early coronary angiogram was performed in each patient, allowing precise evaluation of coronary lesions and optimized acute-phase management. The most suitable treatment was delivered during the first week, according to the guideline recommendations.
Intervention at three months
Assessment of left ventricular ejection fraction and residual myocardial ischaemia
An echocardiography was performed to assess global systolic ventricular function and wall motion abnormalities, complemented by an isotopic measure of ejection fraction. Residual myocardial ischaemia was evaluated by thallium-201 perfusion single-photon emission computed tomography during exercise.
Assessment of atherosclerosis burden
Atherosclerosis burden was evaluated by measuring coronary, carotid and lower-limb atherosclerosis, as follows:
• coronary atherosclerosis: a reduction of ≥ 50% in the diameter of one epicardial vessel on coronary angiography was considered to be a significant coronary stenosis, in addition to the lesion responsible for the ACS; • carotid atherosclerosis: carotid ultrasound duplex imaging measured the intima medial thickness of the far wall of the common carotid arteries [21] and the percentage of internal carotid artery stenosis [22] ;
• lower-limb atherosclerosis: ankle brachial index (ABI) measurement was performed with the patient in the supine position after ≥ 5 min of rest [8] .
Risk factor management and medical treatment
Each patient underwent evaluation of their reported lifestyle in relation to smoking habits, diet and physical activity. Family history of myocardial infarction was identified. Height and weight were measured and body mass index (kg/m 2 ) was calculated. Blood pressure was monitored over the course of 1 h with the patient in the supine position, and the mean measurement was used in the data analysis. A blood sample was drawn by vein puncture after a 12-hour fast to measure lipid concentrations (total cholesterol, high-density lipoprotein and low-density lipoprotein [LDL] cholesterol, triglycerides, lipoprotein[a]), glucose (fasting glucose, HbA1c), creatinine clearance and inflammatory markers (high-sensitive C-reactive protein, fibrinogen).
Diabetes mellitus was defined as fasting glycaemia ≥ 7 mmol/L in two consecutive measures or when antidiabetic drugs had been prescribed previously. Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg. Dyslipidaemia was defined as LDL cholesterol > 3.35 mmol/L.
Treatment at hospital discharge was consistently adapted to cardiac and vascular status, to risk factors and to specific goals to be attained, in accordance with international guidelines [19] . The aim of dietary intervention was a total daily intake of fat < 30% of the daily energy intake and an intake of saturated fatty acids < 10% of the daily energy intake. A dietician provided patient-specific weight-management guidance. On two occasions, educational classes lasting 2 h were provided that covered all aspects of coronary artery disease risk, including lifestyle modification, smoking cessation, hypertension and lipid and diabetes management, and provided comprehensive risk-reduction counselling to improve observance to treatment. A smoking cessation specialist was involved for current smokers. Light-to-moderate exercise lasting ≥ 30 min three times a week was recommended.
Definitions of PVD: organization of patient groups
In order to evaluate the impact of the extent of atherosclerosis lesions on outcome after an ACS, patients were categorized into two groups according to the presence (defined as an ABI < 0.9) or absence of PVD: CAD alone and CAD and PVD.
Patient follow-up and definition of endpoints
Follow-up was carried out with a standardized questionnaire, previously validated in clinical trials [18, 23] , sent to each patient and physician 18 months after discharge from the CEPTA evaluation. Nurses in charge of patient education telephoned the patients at their homes and/or their physicians, whenever needed (i.e., when there was an address and/or phone number change or for medical details). The questionnaire covered aspects of lifestyle habits including former or current smoking and level of physical activity. Symptoms of reinfarction, stroke, PVD and surgical treatment (revascularization by angioplasty, coronary artery bypass grafting, carotid endarterectomy) after hospital discharge were researched. The medical records of the subjects who died, or who reported on the questionnaire that they had experienced symptoms or any clinical outcome between baseline evaluation and follow-up, were reviewed by one of the investigators, and patient practitioners were contacted. The patient's practitioner measured blood pressure and weight. Current medication was noted.
At follow-up, treatments, risk-factor profile and cardiovascular events were evaluated. Events included total events (cardiovascular death, ACS, stroke or transient ischaemic attack [TIA] , congestive heart failure, secondary coronary revascularization or peripheral vascular surgery), major adverse cardiovascular events (MACE; cardiovascular death, ACS, stroke or TIA) and minor adverse cardiovascular events (MICE; congestive heart failure, coronary or peripheral vascular revascularization).
Statistical analysis
Baseline characteristics, ACS management, atherosclerotic lesions, treatment and risk factors at follow-up of patients without PVD were compared with those presenting with PVD using the t test and the 2 test, as appropriate. A Cox proportional-hazards regression analysis in univariate or multivariable models was used for further analysis of independent variables predicting the occurrence of events at follow-up after adjustment for potentially confounding variables. Covariates that were tested in the model included PVD, non-modifiable risk factors (age, sex) and modifiable risk factors (hypertension, smoking, dyslipidaemia and diabetes). With the aim of determining predictors of events, patients who presented an event during follow-up were compared to those who did not by use of the t test for continuous variables and the 2 statistic for categorical variables. Taking these results into account, Cox proportional-hazards regression was used to assess the risk of cardiovascular events in patients with CAD and PVD, with CAD and diabetes, and with CAD and both PVD and diabetes, with hazards ratios given in comparison with CAD alone as a reference group. A p value ≤ 0.05 was considered to be statistically significant. The software for statistical analysis was STATA (StataCorp LP, College Station, Texas).
Results
From January 2002 to June 2005, 851 consecutive men and women presenting with an ACS were hospitalized at CEPTA for an optimized atherosclerosis secondary prevention programme and were enrolled in the study. According to the extent of atherosclerosis, 715 patients (84.0%) presented with CAD alone and 136 patients (16.0%) with CAD and PVD.
Acute phase management and evaluation at three months
Patients with CAD and PVD were more likely than those with CAD alone to receive medical treatment and they had a greater atherosclerotic burden (Table 1) . Table 2 shows the demographic and baseline characteristics of patients three months after the index event. In comparison with CAD alone, patients with both CAD and PVD were older and had a higher prevalence of cardiovascular risk factors despite treatment initiated after the ACS.
Follow-up results
The median length of follow-up was 18.6 months (interquartile range 15.6-24.5). Twenty-six patients died and 29 were lost to follow-up; data were therefore available in 796 (96.6%) eligible patients. In this single-centre study, which included an educational programme and was led by trained nurses who were also in charge of the follow-up, very few patients and/or physicians could not be reached at 18 months. Treatment at follow-up showed a high level of prescription of guideline-recommended secondary prevention drugs in both groups, with no statistical difference between the two, except for a higher number of antihypertensive drugs given to patients with CAD and PVD (Table 3) . Despite a higher prevalence of modifiable cardiovascular risk factors at three-month evaluation in the PVD versus non-PVD group (Table 2) , no significant differences were found at follow-up between the two groups, except for HbA1c, which was higher in patients with CAD and PVD (Table 3) . Moreover, lipid concentrations and blood pressure measures met the target goals recommended by guidelines in a very high proportion of subjects in both groups (Table 3) . Diabetes control was equivalent in the two groups. There was no significant difference between groups in the rate of current smokers or the level of physical activity ( Table 3) .
The incidences of MACE, MICE and total events during follow-up were 13.3%, 8.3% and 21.6%, respectively, in patients with CAD and PVD and 5.8%, 5.0% and 10.8% in patients with CAD alone. In these post-ACS patients receiving optimal secondary prevention treatment, multivariable analysis showed that PVD remained significantly associated with cardiovascular events during follow-up (Tables 4 and 5 ). Analysis of variables influencing the cardiovascular prognosis of this cohort also found a significant and independent influence of diabetes (Table 5) . The risk profile of patients presenting an event during follow-up was compared with that of patients who were event-free, and showed significant differences in fasting glycaemia concentration (6.64 mmol/L vs 5.99 mmol/L, p < 0.001), HbA1c (6.42% vs 5.96%, p > 0.0001), presence of diabetes (36% vs 24%, p < 0.01), poorer control of diabetes (HbA1c 7.3% vs 6.8%, p < 0.05) and presence of PVD (26.3% vs 13.5%, p < 0.0001).
Cox proportional-hazards regression found that, in comparison to CAD alone, in patients with PVD, diabetes was Table 4 Unadjusted and adjusted hazard ratios (95% confidence intervals) for occurrence of total events, MACE and MICE during follow-up after an acute coronary syndrome in patients with peripheral vascular disease (reference group: CAD alone).
Unadjusted
Adjusted associated with a 2.9-fold excess risk of total cardiovascular events whereas no significant risk excess was shown in PVD patients without diabetes. Moreover, diabetes was not significantly associated with the occurrence of cardiovascular events in the absence of PVD (Table 6 ). Thus, the excess morbidity-mortality rate in this cohort of post-ACS patients with improved risk profile could be attributed to the comorbid association of PVD and diabetes, whereas PVD or diabetes separately were not significant predictors of a poorer outcome.
Discussion
These observational data demonstrate that a specialized intervention programme focused on patient education and optimization of treatment can improve both the risk-factor profile of patients and use of evidence-based therapies over the long-term after an ACS, with similar findings in patients with and without PVD. Second, PVD remains a risk marker of cardiovascular events despite optimal secondary prevention following an ACS but is not associated with poorer prognosis in patients without diabetes. Third, the association of diabetes and PVD appears to be the main factor contributing to a more complicated course, whereas diabetes in patients without PVD was not associated with higher cardiovascular morbidity and mortality in patients receiving optimal treatment after an ACS. Coronary patients have a poorer cardiovascular prognosis when lower limb peripheral artery disease is present [4] [5] [6] [7] [8] . Their worse outcome may be attributed in part to less-aggressive treatment during the early management of ACS, greater prevalence of atherosclerosis risk factors and suboptimal use of recommended therapies [15, 16] . Patients with atherothrombotic disease in multiple vascular beds are known to carry a higher residual risk profile than patients with CAD alone [17] . Thus, we sought to treat risk factors more aggressively in an effort to reach established secondary prevention goals. The risk profile of patients with PVD in our study, three months after an ACS, is consistent with previously reported data on secondary prevention failure [5, 15] , showing a high prevalence of residual risk factors three months after an ACS despite secondary prevention measures. The CEPTA programme of global atherosclerosis management demonstrated its efficiency in improving both the rates of use of recommended drug therapies and the long-term cardiovascular risk profile of PVD patients after an ACS. As a result, the two groups of patients met established targets for lipids, glucose and blood pressure a median of 18.6 months after our intervention. To the best of our knowledge, this is the first demonstration that very highrisk patients with ACS and PVD can benefit from such a programme in terms of risk-profile improvement.
Previous studies have shown consistent data on poorer outcomes after an ACS when PVD was present, even in asymptomatic subjects [7, 8, 24] . Our present data suggest that even though optimal long-term medical care reduced cardiovascular risks following an ACS in patients with PVD, it failed to demonstrate any capacity to lower the cardiovascular event rate to that of patients without PVD. The secondary prevention goals may, however, have been insufficient to achieve this aim. Our results are in accordance with a recent report from the REduction of Atherothombosis for Continued Health (REACH) Registry in patients with peripheral artery disease, which showed that good control of cardiovascular risk was not associated significantly with a reduction in the risk of total cardiovascular events [25] .
The prevalence of diabetes mellitus in patients with an ACS was high in the present study, and diabetes has been shown to remain an independent marker of unfavourable prognosis despite improvement in the management of ACS [26] . Our study showed that diabetic subjects without PVD did not have a poorer prognosis than patients without diabetes. In other respects, PVD in non-diabetic patients had no significant implications for outcome. The factor associated with poorer prognosis in patients receiving optimized management was the association of diabetes and PVD, a very high-risk group in which this type of secondary prevention failed.
The reasons for failure of secondary prevention in patients with both PVD and diabetes in this study remain unclear. Patients with PVD were older and at higher risk, but analysis of variables that affect prognosis showed little influence of any except diabetes. The secondary prevention goals of this cohort corresponded to recommended values at the time of the study. Since then, LDL cholesterol goals have been lowered to 1.81 mmol/L in very high-risk patients, including those with PVD [10] . Our study may not evaluate a potential greater benefit of current recommended secondary prevention with lower LDL-cholesterol values. Most recently, both the Action to Control Cardiovascular Risk in Diabetes (ACCORD) and Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) studies failed to demonstrate the efficacy of intensive glycaemic control on the occurrence of macrovascular events in patients with diabetes [27, 28] . In fact, while the microvascular prognosis is improved with treatment of hyperglycaemia, macrovascular prognosis is very poorly affected by glycaemic control in diabetes. In this study, the HbA1c levels of diabetic patients reached the recommended 7% level, which remains the most appropriate target for prevention of macrovascular events. Recent data shed doubt over the protective effect of low-dose aspirin in the prevention of cardiovascular events in diabetic patients with PVD [29] . In this study, a high proportion of patients, including those with diabetes, received low-dose aspirin as recommended for secondary prevention in the long-term after an ACS [29] . In the Steno-2 study, an intervention aimed at several modifiable risk factors was able to reduce the risk of cardiovascular events in type 2 diabetics with microalbuminuria [30, 31] . Our results confirm the efficacy of an intensified multifactorial treatment approach in diabetic patients without PVD, even after an ACS, and are encouraging in non-diabetic subjects with PVD. However, future research should focus on defining new targets for risk factors or new treatment strategies that might improve the outcome of coronary patients with both PVD and diabetes.
Conclusion
These results, with notable clinical implications in the field of secondary prevention, suggest better and earlier identification of a very high-risk coronary population with PVD and diabetes who are in need of secondary prevention reinforcement. Optimization of risk-factor control and drug prescription resulted in a better prognosis for PVD patients without diabetes and for diabetic patients without PVD after an ACS, but was insufficient to control cardiovascular risk in patients with diabetes and PVD.
